These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22939907)

  • 21. Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanon.
    Hanna-Wakim R; Chehab H; Mahfouz I; Nassar F; Baroud M; Shehab M; Pimentel G; Wasfy M; House B; Araj G; Matar G; Dbaibo G;
    Vaccine; 2012 Dec; 30 Suppl 6():G11-7. PubMed ID: 23228352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.
    Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW
    Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.
    Kaplan SL; Barson WJ; Lin PL; Romero JR; Bradley JS; Tan TQ; Hoffman JA; Givner LB; Mason EO
    Pediatr Infect Dis J; 2013 Mar; 32(3):203-7. PubMed ID: 23558320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta.
    Leal J; Vanderkooi OG; Church DL; Macdonald J; Tyrrell GJ; Kellner JD
    Pediatr Infect Dis J; 2012 Sep; 31(9):e169-75. PubMed ID: 22673137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas.
    Techasaensiri C; Messina AF; Katz K; Ahmad N; Huang R; McCracken GH
    Pediatr Infect Dis J; 2010 Apr; 29(4):294-300. PubMed ID: 19949357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
    Regev-Yochay G; Katzir M; Strahilevitz J; Rahav G; Finn T; Miron D; Maor Y; Chazan B; Schindler Y; Dagan R;
    Vaccine; 2017 Apr; 35(18):2449-2456. PubMed ID: 28342668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of Severe and Non-severe Invasive Pneumococcal Disease in Young Children in Israel Following PCV7/PCV13 Introduction.
    Glikman D; Dagan R; Barkai G; Averbuch D; Guri A; Givon-Lavi N; Ben-Shimol S;
    Pediatr Infect Dis J; 2018 Oct; 37(10):1048-1053. PubMed ID: 29750768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period.
    De Serres G; Pilishvili T; Link-Gelles R; Reingold A; Gershman K; Petit S; Farley MM; Harrison LH; Lynfield R; Bennett NM; Baumbach J; Thomas A; Schaffner W; Beall B; Whitney C; Moore M
    Vaccine; 2012 Jun; 30(27):4067-72. PubMed ID: 22525797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Giangaspro E; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
    Pediatr Infect Dis J; 2013 Jun; 32(6):656-61. PubMed ID: 23249906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
    Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
    Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Lexau C; Bennett NM; Petit S; Zansky SM; Harrison LH; Reingold A; Miller L; Scherzinger K; Thomas A; Farley MM; Zell ER; Taylor TH; Pondo T; Rodgers L; McGee L; Beall B; Jorgensen JH; Whitney CG
    Lancet Infect Dis; 2015 Mar; 15(3):301-9. PubMed ID: 25656600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.
    Myint TT; Madhava H; Balmer P; Christopoulou D; Attal S; Menegas D; Sprenger R; Bonnet E
    Adv Ther; 2013 Feb; 30(2):127-51. PubMed ID: 23397399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009-2014.
    Chowers M; Regev-Yochay G; Mor O; Cohen-Poradosu R; Riesenberg K; Zimhony O; Chemtob D; Stein M; Dagan R; Levy I
    Hum Vaccin Immunother; 2017 Jan; 13(1):216-219. PubMed ID: 27648488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance.
    Arifeen SE; Saha SK; Rahman S; Rahman KM; Rahman SM; Bari S; Naheed A; Mannan I; Seraji MH; Ahmed NU; Hassan MS; Huda N; Siddik AU; Quasem I; Islam M; Fatima K; Al-Emran H; Brooks WA; Baqui AH; Breiman RF; Sack D; Luby SP
    Clin Infect Dis; 2009 Mar; 48 Suppl 2():S103-13. PubMed ID: 19191605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.